MicroRNA deregulation in polycythemia vera and essential thrombocythemia patients

Blood Cells, Molecules, and Diseases

Volumn 50, Issue 3, 2013, Pages 190-195

  Zhan, Huichun ^a,b   Cardozo, Christopher ^a,c   Yu, Wayne ^d   Wang, Antai ^b   Moliterno, Alison R ^d   Dang, Chi V ^e   Spivak, Jerry L ^d  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b NewYork Presbyterian Hospital   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Essential thrombocythemia; Hematopoiesis; MicroRNA; Myeloproliferative neoplasm; Polycythemia vera

Indexed keywords

CD34 ANTIGEN; MICRORNA; MICRORNA 145; MICRORNA 196B; MICRORNA 451; MICRORNA 551B; MICRORNA 575; MICRORNA 887; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DNA MICROARRAY; DOWN REGULATION; ERYTHROCYTOSIS; ERYTHROID CELL; ERYTHROID PRECURSOR CELL; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE FUNCTION; GENETIC REGULATION; HUMAN; HUMAN CELL; MALE; MOLECULAR DYNAMICS; PATHOGENESIS; PHENOTYPE; POLYCYTHEMIA VERA; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA DEREGULATION; SEX DIFFERENCE; THROMBOCYTOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; UPREGULATION;

ADULT; AGED; ANTIGENS, CD34; CASE-CONTROL STUDIES; ERYTHROPOIESIS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HEMATOPOIETIC STEM CELLS; HUMANS; MALE; MICRORNAS; MIDDLE AGED; POLYCYTHEMIA VERA; SEX FACTORS; THROMBOCYTHEMIA, ESSENTIAL;

MURINAE;

EID: 84873272524     PISSN: 10799796     EISSN: 10960961     Source Type: Journal    
DOI: 10.1016/j.bcmd.2012.11.009     Document Type: Article

References (51)

1. Baxter E.J., et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005, 365:1054-1061.
2. James C., et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005, 434:1144-1148.
3. Kralovics R., et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N. Engl. J. Med. 2005, 352:1779-1790.
4. Levine R.L., et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005, 7:387-397.
5. Zhao R., et al. Identification of an acquired JAK2 mutation in polycythemia vera. J. Biol. Chem. 2005, 280:22788-22792.
6. Adamson J.W., et al. Polycythemia vera: stem-cell and probable clonal origin of the disease. N. Engl. J. Med. 1976, 295:913-916.
7. Jacobson R.J., Salo A., Fialkow P.J. Agnogenic myeloid metaplasia: a clonal proliferation of hematopoietic stem cells with secondary myelofibrosis. Blood 1978, 51:189-194.
8. Fialkow P.J., et al. Evidence that essential thrombocythemia is a clonal disorder with origin in a multipotent stem cell. Blood 1981, 58:916-919.
9. Tiedt R., et al. Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice. Blood 2008, 111:3931-3940.
10. Xing S., et al. Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice. Blood 2008, 111:5109-5117.
11. Wernig G., et al. Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood 2006, 107:4274-4281.
12. Lacout C., et al. JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. Blood 2006, 108:1652-1660.
13. Chen E., et al. Distinct clinical phenotypes associated with JAK2V617F reflect differential STAT1 signaling. Cancer Cell 2010, 18:524-535.
14. Ambros A. The evolution of our thinking about microRNAs. Nat. Med. 2008, 14:1036-1040.
15. Ambros V., et al. A uniform system for microRNA annotation. RNA 2003, 9:277-279.
16. Kim V.N. MicroRNA biogenesis: coordinated cropping and dicing. Nat. Rev. Mol. Cell Biol. 2005, 6:376-385.
17. Guo S., et al. MicroRNA miR-125a controls hematopoietic stem cell number. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:14229-14234.
18. Ooi A.G., et al. MicroRNA-125b expands hematopoietic stem cells and enriches for the lymphoid-balanced and lymphoid-biased subsets. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:21505-21510.
19. O'Connell R.M., et al. MicroRNAs enriched in hematopoietic stem cells differentially regulate long-term hematopoietic output. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:14235-14240.
20. Lu J., et al. MicroRNA-mediated control of cell fate in megakaryocyte-erythrocyte progenitors. Dev. Cell 2008, 14:843-853.
21. Kumar M.S., et al. Coordinate loss of a microRNA and protein-coding gene cooperate in the pathogenesis of 5q- syndrome. Blood 2011, 118(17):4666-4673.
22. Pelosi E., Labbaye C., Testa U. MicroRNAs in normal and malignant myelopoiesis. Leuk. Res. 2009, 33:1584-1593.
23. Edelstein L.C., Bray P.F. MicroRNAs in platelet production and activation. Blood 2011, 117:5289-5296.
24. O'Connell R.M., Zhao J.L., Rao D.S. MicroRNA function in myeloid biology. Blood 2011, 118:2960-2969.
25. Byon J.C., Papayannopoulou T. MicroRNAs: allies or foes in erythropoiesis?. J. Cell. Physiol. 2012, 227:7-13.
26. Bruchova H., et al. Regulated expression of microRNAs in normal and polycythemia vera erythropoiesis. Exp. Hematol. 2007, 35:1657-1667.
27. Bruchova H., Merkerova M., Prchal J.T. Aberrant expression of microRNA in polycythemia vera. Haematologica 2008, 93:1009-1016.
28. Guglielmelli P., et al. MicroRNA expression profile in granulocytes from primary myelofibrosis patients. Exp. Hematol. 2007, 35:1708-1718.
29. Guglielmelli P., et al. Overexpression of microRNA-16-2 contributes to the abnormal erythropoiesis in polycythemia vera. Blood 2011, 117:6923-6927.
30. Lin X., et al. miR-433 is aberrantly expressed in myeloproliferative neoplasms and suppresses hematopoietic cell growth and differentiation. Leukemia 2012.
31. Moliterno A.R., et al. Phenotypic variability within the JAK2 V617F-positive MPD: roles of progenitor cell and neutrophil allele burdens. Exp. Hematol. 2008, 36:1480-1486.
32. Stein B.L., et al. Sex differences in the JAK2 V617F allele burden in chronic myeloproliferative disorders. Haematologica 2010, 95:1090-1097.
33. Stein B.L., et al. Gender and vascular complications in the JAK2 V617F-positive myeloproliferative neoplasms. Thromb. 2011, 2011:874146.
34. Landolfi R., et al. Polycythemia vera: gender-related phenotypic differences. Intern Emerg Med. 2012, 7(6):509-515.
35. Berk P.D., et al. Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols. Semin. Hematol. 1986, 23:132-143.
36. Kumar M.S., et al. Coordinate loss of a microRNA and protein-coding gene cooperate in the pathogenesis of 5q- syndrome. Blood 2011, 118:4666-4673.
37. Klimchenko O., et al. A common bipotent progenitor generates the erythroid and megakaryocyte lineages in embryonic stem cell-derived primitive hematopoiesis. Blood 2009, 114:1506-1517.
38. Dore L.C., et al. A GATA-1-regulated microRNA locus essential for erythropoiesis. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:3333-3338.
39. Pase L., et al. miR-451 regulates zebrafish erythroid maturation in vivo via its target gata2. Blood 2009, 113:1794-1804.
40. Zhan M., et al. MicroRNA expression dynamics during murine and human erythroid differentiation. Exp. Hematol. 2007, 35:1015-1025.
41. Popovic R., et al. Regulation of mir-196b by MLL and its overexpression by MLL fusions contributes to immortalization. Blood 2009, 113:3314-3322.
42. Arnold C.P., et al. MicroRNA programs in normal and aberrant stem and progenitor cells. Genome Res. 2011, 21:798-810.
43. Scott L.M., et al. Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia. Blood 2006, 108:2435-2437.
44. Yoshida K., et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 2011, 478:64-69.
45. Thol F., et al. Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes. Blood 2012, 119:3578-3584.
46. Hirabayashi S., et al. Spliceosomal gene aberrations are rare, coexist with oncogenic mutations, and are unlikely to exert a driver effect in childhood MDS and JMML. Blood 2012, 119:e96-e99.
47. Makishima H., et al. Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis. Blood 2012, 119:3203-3210.
48. Zhang S.J., et al. Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms reveals recurrent SRSF2 mutations which are associated with adverse outcome. Blood 2012, 119:4480-4485.
49. Bruchova-Votavova H., Yoon D., Prchal J.T. miR-451 enhances erythroid differentiation in K562 cells. Leuk. Lymphoma 2010, 51:686-693.
50. Jamieson C.H., et al. The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:6224-6229.
51. Berkofsky-Fessler W., et al. Transcriptional profiling of polycythemia vera identifies gene expression patterns both dependent and independent from the action of JAK2V617F. Clin. Cancer Res. 2010, 16:4339-4352.